METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline
NICE Methodology Roundtable Discussion
In November 2023 METUPUK trustee Madeleine Meynell was a panel member at the event Optimising NICE outcomes: Policy roundtable on the evolution of NICE methodology and how patient organisations can
Mindfulness and Metastatic Breast Cancer at Christmas
Living with an incurable form of cancer presents lots of physical, emotional and mental challenges not least of which are the expectations and pressures associated with annual celebrations and milestones;
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
“Fighting” Metastatic Breast Cancer Platitudes
Seagen Biotech company asked two metastatic breast cancer (MBC) advocates Eva Schumacher from Mamma Mia online German cancer magazine and patient living with MBC and myself Jo Taylor founder of
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
Our friend Connie Johncock
METUPUK are devastated by the news that one of our Trustees and friend Connie Johncock has died. Connie was a founder trustee of METUPUK and our Treasurer, overseeing our finances as we
Aren’t you a bit young to have a pacemaker
Stage 4 breast cancer with a pacemaker
Most people know someone with a pacemaker, and chances are that person will be elderly. The average age of a first pacemaker implantation in the UK is 72, but pacemakers are actually fitted in people of all ages from newborn babies to the very elderly. I was 39 when I had mine, which was needed as a complication after heart surgery to replace my aortic valve and root.